The average internal rate of return from research and development at the world's 12 biggest drugmakers dropped from 11.8% to 8.4% over the past year, according to a study by Deloitte and Thomson Reuters. The industry is likely to respond by collaborating more and sharing capabilities, said Julian Remnant, head of Deloitte's European R&D advisory practice.

Full Story:

Related Summaries